Plenary Sessions
Monday, June 2, 2014
9:00 AM - 10:30 AM
FIRST PLENARY SESSION: THE USE OF "BIG DATA" - WHERE ARE WE AND WHAT DOES THE FUTURE HOLD?
This session will focus on two methodological approaches to the analysis of big data: (1) Graph Analytics approaches which facilitate the linkage of datasets with much less investment in initial data modelling and (2) Machine Learning approaches-many of which are closely related to traditional statistical methods from health services research, epidemiology, and health econometrics. The session will consider how these different approaches deal with issues of data quality and data completeness and the implications for the confidence in the conclusions drawn from such analyses.
Moderator: Marcus Wilson, PharmD bio
President, HealthCore, Wilmington, DE, USA
Using Big Data in Health Care – Graph Databases and Graph Analytics Approaches
Speaker: David R. Holmes III, PhD bio
Collaborative Scientist, Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, MN, USA
Using Big Data in Health Care – Statistical Caution When Using Big Data – Linking Medical Records and Health Care Transactions
Speaker: William H. Crown, PhD bio
Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
Comparison of Machine Learning & Traditional Outcomes Research Methods from a Researcher’s Perspective
Speaker: Lesley H. Curtis, PhD bio
Professor in Medicine, Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC, USA
Discussion
Tuesday, June 3, 2014
9:00 AM - 10:30 AM
SECOND PLENARY SESSION: WHAT ARE THE ADVANTAGES AND DISADVANTAGES OF USING OBSERVATIONAL DATA AS THE BASIS OF DECISION MAKING IN HEALTH CARE? HOW COULD THIS AFFECT THE FUTURE OF RANDOMIZED CONTROLLED TRIALS?
This session will focus on the use of observational data (administrative data as well as prospective observational data) studies in health care decision making. The arguments of randomized controlled trials versus 'real world' observational studies (internal/external validity, bias) will be debated.
Moderator: Leslie Levin, FRCP(Lon), FRCPC bio
Chief Scientific Officer, MaRS EXCITE, Vice President, Evidence Development and Standards, Health Quality Ontario, and Professor of Medicine, University of Toronto, Toronto, ON, Canada
Is It Time to Retire the Randomized Controlled Trial?
Speaker: David Sackett, OC, FRSC, MD, MSc, FRCP bio
Professor Emeritus, Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada
Using Observational Data to Estimate Benefits and Harms of Health Care Interventions
Speaker: David Henry, MB ChB, MRCP, FRCP bio
Senior Scientist, ICES Central and Professor, University of Toronto, Toronto, ON, Canada
The Value of Observational Data in Health Care Decisions
Speaker: Allan M. Korn, MD, FACP bio
Chief Medical Officer Emeritus, Blue Cross and Blue Shield Association (BCBSA), Chicago, IL, USA
Wednesday, June 4, 2014
9:45 AM - 11:00 AM
THIRD PLENARY SESSION: TO WHAT EXTENT SHOULD VALUE FOR MONEY DERIVED FROM HEALTH ECONOMIC ANALYSIS BE USED IN HEALTH CARE POLICY DECISION MAKING?
This session will focus on whether or how value for money is being used in health care policy decision making in government and private insurance companies. The pros and cons of the different types of economic analysis currently used to determine value for money as well as ethical issues will be debated.
Moderator: Don Husereau, MSc, BScPharm bio
Senior Associate, Institute of Health Economics, Adjunct Professor, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
Speaker: Tony Culyer, Hon DEcon, Hon FRCP, FRSA, FMedSci bio
Ontario Research Chair in Health Policy and System Design, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Speaker: Colleen M. Flood, LLM, SJD bio
Canada Research Chair in Health Law and Policy, Faculty of Law, University of Toronto, Toronto, ON, Canada
Speaker: Honourable Minister Fred Horne bio
Government of Alberta, Ministry of Health, Edmonton, AB, Canada
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.